By combining the use of BD Biosciences Fluoro Blok ™ membrane-based Boyden chambers with the Cellomics HCS Array Scan, a more sensitive method formeasuring cellmigration has been developed. This assay is based on counting nuclei ofmigrated cells on the bottomof the filter rather than conventional approaches, which usemeasurement of totalwell fluorescence. This cellmigration assay provides approximately 10-fold increased signal/background compared to conventional approaches and can be used to assess the effects of growth factors on endothelial cell migration and to screen chemical compounds for inhibitory effects on growth factor–mediated endothelial cell migration.
Stupack DG, Cho SY, Klemke RL: Molecular signaling mechanisms of cell migration and invasion. Immunol Res2000;21:83-88. Mastyugin et al.
2.
Cockerill GW, Gamble JR, Vadas MA: Angiogenesis: models and modulators. Int Rev Cytol1995;159:113-160.
3.
Fan TP, Polverini PJ: In vivo models of angiogenesis. In Bicknell R, Lewis CE, Ferrara N (eds): Tumor Angiogenesis. Oxford, UK: Oxford University Press, 1997:5-18.
4.
Jain RK, Schlenger K, Hockel M, Yuan F: Quantitative angiogenesis assays: progress and problems. Nat Med1997;3:1203-1208.
5.
Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol1992;119:493-501.
6.
Parent CA, Devreotes PN: Acell's sense of direction. Science1999;284:765-770.
7.
Montesano R, Pepper MS, Vassalli JD, Orci L: Modulation of angiogenesis in vitro. EXS1992;61:129-136.
8.
Jin T, Zhang N, Long Y, Parent CA, Devreotes PN: Localization of theGprotein betagamma complex in living cells during chemotaxis. Science2000;287:1034-1036.
Boyden S: The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leukocytes. J Exp Med1962;115:453-466.
11.
Goldberger A, Septak M: BD Biosciences Discovery Labware. Technical Bulletin 428, 1998. Retrieved from http://www.bdbiosciences.com/discovery_labware/technical_resources/pdf/tb428.pdf
12.
Maliakal JC: Quantitative high throughput endothelial cell migration and invasion assay system. Methods Enzymol2002;352:175-182.
13.
Bold G, Altmann KH, Frei J, et al: New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J Med Chem2000;43:2310-2323.
14.
Drevs J, Muller-Driver R, Wittig C, et al: PTK787/ZK222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res2002;62:4015-4022.
15.
Solorzano CC, Baker CH, Bruns CJ, et al: Inhibition of growth andmetastasis of human pancreatic cancer growing in nude mice by PTK787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm2001;16:359-370.
16.
Drevs J, Hofmann I, Hugenschmidt H, et al: Effects of PTK787/ZK222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flowin amurine renal cell carcinoma model. Cancer Res2000;60:4819-4824.
17.
Wood JM, Bold G, Buchdunger E, et al: PTK787/ZK222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res2002;60:2178-2189.
18.
Wood JM: Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy. Medicina (B Aires)2000;60(suppl 2):41-47.
19.
Manley PW, Furet P, Bold G, et al: Anthranilic acid amides: a novel class of antiangiogenicVEGF receptor kinase inhibitors. J Med Chem2002;45:5687-5693.
Millauer B, Wizigmann-Voos S, Schnurch H, et al: High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell1993;72:835-846.
22.
Fong GH, Rossant J, Gertsenstein M, Breitman ML: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature1995;376:66-70.
23.
Shalaby F, Ho J, Stanford WL, et al: A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell1997;89:981-990.
24.
Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J1999;13:9-22.
25.
Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K: Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res2000;60:203-212.
26.
Joukov V, Pajusola K, Kaipainen A, et al: Anovel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) andKDR(VEGFR-2) receptor tyrosine kinases. EMBO J1996;15:290-298.
27.
Makinen T, Jussila L, Veikkola T, et al: Inhibition of lymphangiogenesis with resulting lymphedema in transgenicmice expressing solubleVEGF receptor-3. Nat Med2001;7:199-205.
28.
Zhang JH, Chung TDY, Oldenburg KR: Asimple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen1999;4:67-73.
